Biosimilarity and Interchangeability: Additional Draft Q&As on Biosimilar Development and the BPCI Act (Revision 1)
Biosimilarity
Stay updated with breaking news from Docket Number. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This guidance describes FDA’s participation in the Voluntary Improvement Program (VIP). The VIP is a voluntary program intended to guide improvement to enhance the quality of devices.
Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry
Last week, the IRS announced “the start of a sweeping, historic effort to restore fairness in tax compliance by shifting more attention onto high-income earners, partnerships, large...
On August 29, 2023, the U.S. Fish and Wildlife Service (Service) published a final rule listing two distinct population segments (DPS)—the North Feather and Central Coast DPSs—of the...